Responses
Oncolytic and local immunotherapy
Original research
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Compose a Response to This Article
Other responses
No responses have been published for this article.